| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue, net | 60,112 | 189,757 | NaN | NaN |
| Cost of sales | 7,157 | NaN | NaN | NaN |
| Cost of sales | 7,157 | 19,492 | NaN | NaN |
| Global headcount expense | 58,653 | 172,648 | NaN | NaN |
| Preclinical, clinical and development expense | 18,511 | 87,322 | NaN | NaN |
| Commercial & medical affairs | 20,264 | 66,963 | NaN | NaN |
| Corporate, general & administrative | 7,888 | 35,348 | NaN | NaN |
| Other segment expenses | NaN | 0 | NaN | NaN |
| Other (income) expense, net | NaN | -1,264 | NaN | NaN |
| Other income (expense), net | -1,704 | NaN | NaN | NaN |
| Interest income (expense), net | 1,029 | -5,290 | NaN | NaN |
| Income taxes | 545 | 497 | NaN | NaN |
| Net loss | -55,639 | -47,505 | -52,904 | -96,130 |
| Stock-based compensation expense | 23,099 | 19,266 | 18,810 | 28,742 |
| Depreciation and amortization | 252 | 272 | 304 | 762 |
| Non-cash interest expense | 4,577 | 4,616 | 4,742 | 11,226 |
| Non-cash accretion & amortization of short-term investments | -1,436 | -1,855 | -1,695 | -2,966 |
| Non-cash rent expense | 113 | 109 | 104 | 215 |
| Change in fair value of embedded derivative liability | 330 | -130 | -360 | -420 |
| Gain on settlement of forward contract | NaN | 0 | NaN | NaN |
| Acquired ipr&d assets classified as investing activities | NaN | 0 | NaN | NaN |
| Foreign currency (gain) loss | -1,791 | NaN | -1,270 | 1,709 |
| Other non-cash items | -178 | -90 | NaN | NaN |
| Accounts receivable | 8,110 | -6,175 | 6,600 | 7,145 |
| Inventory | 3,086 | 4,927 | 2,451 | 96 |
| Prepaid expenses and other current assets | 487 | 2,707 | -6,385 | 10,005 |
| Deferred revenue | -145 | 194 | 0 | -1,286 |
| Other long-term assets, net | -435 | 681 | 5,242 | -5,526 |
| Accounts payable, accrued expenses and other liabilities | -5,618 | 1,255 | 11,015 | 9,622 |
| Net cash used in operating activities | -44,185 | -25,389 | -26,622 | -63,664 |
| Purchases of short-term investments | 42,199 | 20,347 | 267,847 | 60,475 |
| Maturities of short-term investments | 99,251 | 51,647 | 61,500 | 139,322 |
| Acquisition of ipr&d assets | NaN | 0 | 40,000 | NaN |
| Purchases of property and equipment | NaN | 953 | NaN | NaN |
| Net cash provided by investing activities | 57,052 | 30,347 | -246,347 | 78,847 |
| Repayment of deferred royalty obligation | 4,288 | 5,400 | 5,570 | 8,947 |
| Proceeds from issuance of common stock-Public Offering | NaN | NaN | 188,655 | NaN |
| Proceeds from issuance of common stock upon completion of public offering, net of offering costs | NaN | 188,657 | NaN | NaN |
| Proceeds from the exercise of stock options | 6,095 | 2,449 | 5,486 | 5,669 |
| Tax withholding on vesting of restricted stock | 8,458 | NaN | NaN | NaN |
| Proceeds from issuance of common stock from espp | 1,251 | 1 | 729 | 854 |
| Proceeds from atm equity offering | 0 | 1 | NaN | 34,034 |
| Proceeds from royalty financing agreement, net of issuance costs | NaN | 0 | NaN | NaN |
| Gain on settlement of forward contract | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock-At Market Offerings | NaN | NaN | 34,035 | NaN |
| Proceeds from series a preferred stock, net of issuance costs | NaN | 0 | NaN | NaN |
| Net cash provided by financing activities | -5,400 | -2,948 | 189,301 | 31,610 |
| Effect of exchange rates on cash | 448 | 64 | 304 | -281 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 7,915 | 2,074 | -83,364 | 46,512 |
| Cash, cash equivalents and restricted cash at beginning of period | 54,823 | 52,749 | 89,601 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 62,738 | 54,823 | 52,749 | NaN |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)